Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    ISS22810034
Show Display Options
Rank Status Study
1 Active, not recruiting Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer
Conditions: Stage III Ovarian Cancer;   Stage IV Ovarian Cancer;   Uterine Cancer
Interventions: Drug: Olaparib;   Drug: Carboplatin;   Drug: Paclitaxel

Indicates status has not been verified in more than two years